Cargando…
The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus
Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TAC...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987033/ https://www.ncbi.nlm.nih.gov/pubmed/35388064 http://dx.doi.org/10.1038/s41598-022-09609-8 |
_version_ | 1784682648218632192 |
---|---|
author | Zhang, Weihua Wu, Linxia Chen, Lei Sun, Tao Ren, Yanqiao Sun, Bo Zhu, Licheng Han, Ping Zheng, Chuansheng |
author_facet | Zhang, Weihua Wu, Linxia Chen, Lei Sun, Tao Ren, Yanqiao Sun, Bo Zhu, Licheng Han, Ping Zheng, Chuansheng |
author_sort | Zhang, Weihua |
collection | PubMed |
description | Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TACE-A) in the treatment of HCC with portal vein tumor thrombus (PVTT). A total of 130 continuous patients who received D-TACE-A or C-TACE-A were included in the study from January 2017 to June 2020. Propensity score matching (PSM) was used to reduce potential selection bias. Before PSM, the median overall survival (mOS) (14 months) and median progression-free survival (mPFS) (7 months) in the C-TACE-A group were longer than the mOS (9 months; P = 0.001) and mPFS (4 months; P = 0.001) in the D-TACE-A group. After PSM, the mOS (14 months vs 9 months; P = 0.039) and mPFS (7 months vs 5 months; P = 0.009) in the C-TACE-A group were longer than those in the D-TACE-A group. In the multivariate regression analysis, C-TACE-A reduced the mortality rate and tumor progression rate compared with D-TACE-A. For the subgroup analysis, patients with VP1–2, without extrahepatic metastases, and with multiple TACE sessions who received C-TACE-A had a lower death risk and tumor progression risk than patients who received D-TACE-A. Before PSM, there was no statistically significant difference in any grade or grade III/IV adverse events (all P > 0.05). C-TACE-A could prolong mOS and mPFS in patients with PVTT, especially for patients with VP1–2 stage PVTT, no extrahepatic tumor metastases, and multiple TACE sessions. |
format | Online Article Text |
id | pubmed-8987033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89870332022-04-08 The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus Zhang, Weihua Wu, Linxia Chen, Lei Sun, Tao Ren, Yanqiao Sun, Bo Zhu, Licheng Han, Ping Zheng, Chuansheng Sci Rep Article Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TACE-A) in the treatment of HCC with portal vein tumor thrombus (PVTT). A total of 130 continuous patients who received D-TACE-A or C-TACE-A were included in the study from January 2017 to June 2020. Propensity score matching (PSM) was used to reduce potential selection bias. Before PSM, the median overall survival (mOS) (14 months) and median progression-free survival (mPFS) (7 months) in the C-TACE-A group were longer than the mOS (9 months; P = 0.001) and mPFS (4 months; P = 0.001) in the D-TACE-A group. After PSM, the mOS (14 months vs 9 months; P = 0.039) and mPFS (7 months vs 5 months; P = 0.009) in the C-TACE-A group were longer than those in the D-TACE-A group. In the multivariate regression analysis, C-TACE-A reduced the mortality rate and tumor progression rate compared with D-TACE-A. For the subgroup analysis, patients with VP1–2, without extrahepatic metastases, and with multiple TACE sessions who received C-TACE-A had a lower death risk and tumor progression risk than patients who received D-TACE-A. Before PSM, there was no statistically significant difference in any grade or grade III/IV adverse events (all P > 0.05). C-TACE-A could prolong mOS and mPFS in patients with PVTT, especially for patients with VP1–2 stage PVTT, no extrahepatic tumor metastases, and multiple TACE sessions. Nature Publishing Group UK 2022-04-06 /pmc/articles/PMC8987033/ /pubmed/35388064 http://dx.doi.org/10.1038/s41598-022-09609-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Weihua Wu, Linxia Chen, Lei Sun, Tao Ren, Yanqiao Sun, Bo Zhu, Licheng Han, Ping Zheng, Chuansheng The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title_full | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title_fullStr | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title_full_unstemmed | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title_short | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
title_sort | efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987033/ https://www.ncbi.nlm.nih.gov/pubmed/35388064 http://dx.doi.org/10.1038/s41598-022-09609-8 |
work_keys_str_mv | AT zhangweihua theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT wulinxia theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT chenlei theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT suntao theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT renyanqiao theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT sunbo theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT zhulicheng theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT hanping theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT zhengchuansheng theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT zhangweihua efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT wulinxia efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT chenlei efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT suntao efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT renyanqiao efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT sunbo efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT zhulicheng efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT hanping efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT zhengchuansheng efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus |